Header Logo

Lei Duan

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentAnatomy and Cell Biology
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus number is 55729339900
    My NIH COMMONS name is LDUAN1

    Research Areas:
    Basic and translational cancer research with a focus on understanding molecular mechanisms underlying cancer therapy resistance.

    My Faculty Profile at Rush University Medical Center:
    https://www.rushu.rush.edu/faculty/lei-duan-md

    My Laboratory:
    https://www.rushu.rush.edu/research/departmental-research/cell-molecular-medicine-research/laboratory-lei-duan-md

    My NCBI Bibliography:
    https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48065659/?sort=date&direction=descending

    My Scopus:
    https://www.scopus.com/authid/detail.uri?authorId=55729339900

    Education:
    MD, Shanghai Jiaotong University Medical School, China

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Duan L, Tadi MJ, O'Hara KM, Maki CG. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375. PMID: 38762181; PMCID: PMC11208921.
      Citations:    
    2. Duan L, Maki CG. Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer. Transl Lung Cancer Res. 2024 Feb 29; 13(2):223-228. PMID: 38496702; PMCID: PMC10938090.
      Citations:    
    3. Duan L, Maki CG. Potential biomarkers for MCL1 inhibitor sensitivity. Cell Signal (Middlet). 2024; 2(1):144-147. PMID: 39802137; PMCID: PMC11720113.
      Citations:    
    4. Duan L, Tadi MJ, Maki CG. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271. PMID: 37759078.
      Citations:    
    5. Duan L, Calhoun SJ, Perez RE, Macias V, Mir F, Gattuso P, Maki CG. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10. PMID: 36332175.
      Citations:    
    6. Duan L, Perez RE, Calhoun S, Maki CG. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75. PMID: 35100078.
      Citations:    
    7. Kumar S, Das S, Sun J, Huang Y, Singh SK, Srivastava P, Sondarva G, Nair RS, Viswakarma N, Ganesh BB, Duan L, Maki CG, Hoskins K, Danciu O, Rana B, Li S, Rana A. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119. PMID: 36095190.
      Citations:    
    8. Duan L, Perez RE, Calhoun S, Maki CG. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525. PMID: 35296774.
      Citations:    
    9. Calhoun S, Duan L, Maki CG. Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Transl Oncol. 2022 May; 19:101386. PMID: 35263700.
      Citations:    
    10. Duan L, Calhoun S, Perez RE, Macias V, Mir F, Pergande MR, Gattuso P, Borgia JA, Maki CG. Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jan 31; 14(3). PMID: 35159006.
      Citations:    
    11. Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG. Corrigendum to 'Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells'. J Mol Cell Biol. 2022 Jan 29; 13(12):922. PMID: 35092683.
      Citations:    
    12. Duan L, Perez RE, Calhoun S, Maki CG. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049. PMID: 35058503.
      Citations:    
    13. Dong Q, Wang D, Li L, Wang J, Li Q, Duan L, Yin H, Wang X, Liu Y, Yuan G, Pan Y. Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. Mol Neurobiol. 2022 Feb; 59(2):1262-1272. PMID: 34981417.
      Citations:    
    14. Shim D, Duan L, Maki CG. Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903. PMID: 35582378.
      Citations:    
    15. Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444. PMID: 33755174.
      Citations:    
    16. Shim D, Duan L, Maki CG. P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95. PMID: 34532654.
      Citations:    
    17. Perez RE, Calhoun S, Shim D, Levenson VV, Duan L, Maki CG. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040. PMID: 33044914.
      Citations:    
    18. Duan L, Perez RE, Lai X, Chen L, Maki CG. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197. PMID: 31036564.
      Citations:    
    19. Duan L, Perez RE, Chastain PD, Mathew MT, Bijukumar DR, Maki CG. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657. PMID: 30967636.
      Citations:    
    20. Duan L, Perez RE, Maki CG. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260. PMID: 30289354.
      Citations:    
    21. Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340. PMID: 29190376.
      Citations:    
    22. Zhou Y, Perez RE, Duan L, Maki CG. DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a. Cancer Biol Ther. 2018 06 03; 19(6):465-474. PMID: 29394130.
      Citations:    
    23. Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903. PMID: 28696156.
      Citations:    
    24. Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res. 2017 01 13; 19(1):6. PMID: 28086982.
      Citations:    
    25. Duan L, Maki CG. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675. PMID: 28966916.
      Citations:    
    26. Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26. PMID: 27050276.
      Citations:    
    27. Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47. PMID: 27022024.
      Citations:    
    28. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Alg?l H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, B?nhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolom? A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, B?dard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, B?nard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, B?ckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouch? M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, B?tikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ce?a V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. PMID: 26799652.
      Citations:    
    29. Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56. PMID: 26337205.
      Citations:    
    30. Duan L, Danzer B, Levenson VV, Maki CG. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300. PMID: 25069039.
      Citations:    
    31. Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705. PMID: 24936056.
      Citations:    
    32. Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12. PMID: 25482935.
      Citations:    
    33. Xu S, Zhuang X, Pan X, Zhang Z, Duan L, Liu Y, Zhang L, Ren X, Ding K. 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor a. J Med Chem. 2013 Jun 13; 56(11):4631-40. PMID: 23656512.
      Citations:    
    34. Ortega-Cava CF, Raja SM, Laiq Z, Bailey TA, Luan H, Mohapatra B, Williams SH, Ericsson AC, Goswami R, Dimri M, Duan L, Band V, Naramura M, Band H. Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. J Carcinog. 2011; 10:29. PMID: 22190871.
      Citations:    
    35. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011 Jan 15; 11(2):263-76. PMID: 21088503.
      Citations:    
    36. Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV. Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011 Jan 28; 286(4):2864-76. PMID: 21087932.
      Citations:    
    37. Duan L, Raja SM, Chen G, Virmani S, Williams SH, Clubb RJ, Mukhopadhyay C, Rainey MA, Ying G, Dimri M, Chen J, Reddi AL, Naramura M, Band V, Band H. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem. 2011 Jan 07; 286(1):620-33. PMID: 20940296.
      Citations:    
    38. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, Rainey MA, Dimri M, Ortega-Cava CF, Zhao X, Clubb RJ, Tu C, Reddi AL, Naramura M, Band V, Band H. Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem. 2010 Jan 08; 285(2):1555-68. PMID: 19826000.
      Citations:    
    39. Duan L, Yang J, Slaughter MM. Caffeine inhibition of ionotropic glycine receptors. J Physiol. 2009 Aug 15; 587(Pt 16):4063-75. PMID: 19564396.
      Citations:    
    40. Zhao X, Lu L, Pokhriyal N, Ma H, Duan L, Lin S, Jafari N, Band H, Band V. Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells. Cancer Res. 2009 Jan 15; 69(2):483-91. PMID: 19147561.
      Citations:    
    41. Hou M, Duan L, Slaughter MM. Synaptic inhibition by glycine acting at a metabotropic receptor in tiger salamander retina. J Physiol. 2008 Jun 15; 586(12):2913-26. PMID: 18440992.
      Citations:    
    42. Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M, Band V, Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. J Biol Chem. 2007 Oct 05; 282(40):29336-47. PMID: 17620338.
      Citations:    
    43. Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A. 2007 Mar 27; 104(13):5413-8. PMID: 17372230.
      Citations:    
    44. Gan H, He X, Duan L, Mirabile-Levens E, Kornfeld H, Remold HG. Enhancement of antimycobacterial activity of macrophages by stabilization of inner mitochondrial membrane potential. J Infect Dis. 2005 Apr 15; 191(8):1292-300. PMID: 15776376.
      Citations:    
    45. Duan L, Huang Y, Hao J, Xie S, Hou M. Vegetation uptake of nitrogen and base cations in China and its role in soil acidification. Sci Total Environ. 2004 Sep 01; 330(1-3):187-98. PMID: 15325168.
      Citations:    
    46. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity. 2004 Jul; 21(1):7-17. PMID: 15345216.
      Citations:    
    47. Ghosh AK, Reddi AL, Rao NL, Duan L, Band V, Band H. Biochemical basis for the requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation of a target tyrosine kinase. J Biol Chem. 2004 Aug 20; 279(34):36132-41. PMID: 15208330.
      Citations:    
    48. Miura-Shimura Y, Duan L, Rao NL, Reddi AL, Shimura H, Rottapel R, Druker BJ, Tsygankov A, Band V, Band H. Cbl-mediated ubiquitinylation and negative regulation of Vav. J Biol Chem. 2003 Oct 03; 278(40):38495-504. PMID: 12881521.
      Citations:    
    49. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem. 2003 Aug 01; 278(31):28950-60. PMID: 12754251.
      Citations:    
    50. Duan L, Gan H, Golan DE, Remold HG. Critical role of mitochondrial damage in determining outcome of macrophage infection with Mycobacterium tuberculosis. J Immunol. 2002 Nov 01; 169(9):5181-7. PMID: 12391235.
      Citations:    
    Duan's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (280)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _